

HR 3008

Drug Shortage Prevention Act of 2023

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 28, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 5, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/3008>

Sponsor

Name: Rep. Jacobs, Sara [D-CA-51]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (49 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Apr 28, 2023
Rep. Allred, Colin Z. [D-TX-32]	D · TX		Apr 28, 2023
Rep. Blunt Rochester, Lisa [D-DE-At Large]	D · DE		Apr 28, 2023
Rep. Caraveo, Yadira [D-CO-8]	D · CO		Apr 28, 2023
Rep. Carter, Troy [D-LA-2]	D · LA		Apr 28, 2023
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Apr 28, 2023
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Apr 28, 2023
Rep. Cohen, Steve [D-TN-9]	D · TN		Apr 28, 2023
Rep. Crockett, Jasmine [D-TX-30]	D · TX		Apr 28, 2023
Rep. Doggett, Lloyd [D-TX-37]	D · TX		Apr 28, 2023
Rep. Garcia, Jesus G. "Chuy" [D-IL-4]	D · IL		Apr 28, 2023
Rep. Grijalva, Raúl M. [D-AZ-7]	D · AZ		Apr 28, 2023
Rep. Huffman, Jared [D-CA-2]	D · CA		Apr 28, 2023
Rep. Jackson Lee, Sheila [D-TX-18]	D · TX		Apr 28, 2023
Rep. Khanna, Ro [D-CA-17]	D · CA		Apr 28, 2023
Rep. Kim, Andy [D-NJ-3]	D · NJ		Apr 28, 2023
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Apr 28, 2023
Rep. Larson, John B. [D-CT-1]	D · CT		Apr 28, 2023
Rep. Lee, Barbara [D-CA-12]	D · CA		Apr 28, 2023
Rep. McGovern, James P. [D-MA-2]	D · MA		Apr 28, 2023
Rep. Mills, Cory [R-FL-7]	R · FL		Apr 28, 2023
Rep. Ocasio-Cortez, Alexandria [D-NY-14]	D · NY		Apr 28, 2023
Rep. Pressley, Ayanna [D-MA-7]	D · MA		Apr 28, 2023
Rep. Schiff, Adam B. [D-CA-30]	D · CA		Apr 28, 2023
Rep. Smith, Adam [D-WA-9]	D · WA		Apr 28, 2023
Rep. Tokuda, Jill N. [D-HI-2]	D · HI		Apr 28, 2023
Rep. Veasey, Marc A. [D-TX-33]	D · TX		Apr 28, 2023
Rep. Velazquez, Nydia M. [D-NY-7]	D · NY		Apr 28, 2023
Rep. Watson Coleman, Bonnie [D-NJ-12]	D · NJ		Apr 28, 2023
Rep. Castor, Kathy [D-FL-14]	D · FL		Jun 5, 2023
Rep. Craig, Angie [D-MN-2]	D · MN		Jun 6, 2023
Rep. Slotkin, Elissa [D-MI-7]	D · MI		Jun 12, 2023
Rep. Bice, Stephanie I. [R-OK-5]	R · OK		Jun 14, 2023
Rep. Sarbanes, John P. [D-MD-3]	D · MD		Jun 15, 2023
Rep. Dean, Madeleine [D-PA-4]	D · PA		Jun 20, 2023
Rep. Ryan, Patrick [D-NY-18]	D · NY		Jun 21, 2023
Rep. Davids, Sharice [D-KS-3]	D · KS		Jul 11, 2023
Rep. Deluzio, Christopher R. [D-PA-17]	D · PA		Jul 11, 2023
Rep. Fletcher, Lizzie [D-TX-7]	D · TX		Jul 11, 2023
Rep. Cárdenas, Tony [D-CA-29]	D · CA		Jul 17, 2023
Rep. Peters, Scott H. [D-CA-50]	D · CA		Jul 20, 2023

Cosponsor	Party / State	Role	Date Joined
Rep. Hoyle, Val T. [D-OR-4]	D · OR		Jul 26, 2023
Rep. Frost, Maxwell [D-FL-10]	D · FL		Aug 29, 2023
Rep. Leger Fernandez, Teresa [D-NM-3]	D · NM		Nov 14, 2023
Rep. Lynch, Stephen F. [D-MA-8]	D · MA		Dec 5, 2023
Rep. Quigley, Mike [D-IL-5]	D · IL		Jun 4, 2024
Rep. Pappas, Chris [D-NH-1]	D · NH		Jul 5, 2024
Rep. Tlaib, Rashida [D-MI-12]	D · MI		Jul 10, 2024
Rep. Tonko, Paul [D-NY-20]	D · NY		Jul 18, 2024

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 5, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 4697	Related bill	Jul 21, 2023: Referred to the Subcommittee on Health.

Summary (as of Apr 28, 2023)

Drug Shortage Prevention Act of 2023

This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand for certain critical essential medicines that may result in a shortage.

Currently, drug manufacturers are required to notify the FDA in the event of a discontinuation or interruption in the supply of prescription drugs that are life-supporting, life-sustaining, or used for a debilitating disease or condition, including those used in medical emergencies, surgeries, or public health emergencies.

The bill requires drug manufacturers to also notify the FDA if there is an increased demand for such drugs that lasts for at least six weeks and that may result in a shortage. Manufacturers must initially notify the FDA of the increased demand within 48 hours after this six-week period and must submit an additional notice within 30 days of the initial notification. The notice must include the reasons for the increased demand, the expected duration, and any other information the FDA requires. The bill's requirements apply to both prescription and nonprescription drugs.

Actions Timeline

- **May 5, 2023:** Referred to the Subcommittee on Health.
- **Apr 28, 2023:** Introduced in House
- **Apr 28, 2023:** Referred to the House Committee on Energy and Commerce.